James Waldron

Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here... fiercebiotech.com/biotech/jpm25-…

For this week's @FierceBiotech podcast, I caught up with @novonordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer fiercepharma.com/pharma/novo-no…

My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)

The KarXT crown looks secure in Bristol Myers' hands for a while at least

While the in vivo program is taking center stage, @editasmed told me work on reni-cel is not being halted, with a “substantive clinical data set” lined up for #ASH24

Today's news throws a spanner in two programs that CEO John Jacobs had been pointing to as potential growth drivers for the company fiercebiotech.com/biotech/fda-pu…

At LSX in April, Gateway Labs' Julie Gilmore told me they planned to "go to geographies where we think we can make a difference.” Now it turns out one of those will be the UK... fiercebiotech.com/biotech/lilly-…

This morning sees another 2 biotechs joining the steady trickle of IPOs. Upstream has upsized its offering while CAMP4 has rebalanced its own $UBP $CAMP fiercebiotech.com/biotech/upstre…

Sanofi's head of R&D told me the company will engage with the FDA “as soon as possible” to discuss filing for approval in non-relapsing secondary progressive MS

Sanofi’s tolebrutinib failed 2 out of 3 phase 3 MS trials that read out this morning, but the pharma is still planning an FDA filing fiercebiotech.com/biotech/sanofi…

Looks like Bayer's Juergen Eckhardt was right when he told @fierce in June that he wouldn't let the company's restructuring affect their push for oncology innovation fiercebiotech.com/biotech/bayer-…

@HughLangley Nice interview!

Went on Times Radio for an Elon-Trump curtain raiser. Also discussed possibility of Trump making a full return to X which, of course, was rendered moot about an hour after this went out

.@FierceBiotech editor @GabrielleMasso9 was interviewed on the NYSE floor this morning! She shared insights on Fierce Biotech's Fierce 15 this year, the use of AI and other trends in the biotech market. Her segment starts at the 40:00 mark

Our recently announced partnership with @GSK will develop a portfolio of entirely new medicines and vaccines to address unmet needs initially focused in respiratory and immunology. For more, read this @FierceBiotech piece by @JamesPharma: fiercebiotech.com/biotech/gsk-be…

I noticed J&J had removed its Addex-partnered epilepsy drug from its pipeline. Turns out the Big Pharma had lost faith after April's phase 2 fail fiercebiotech.com/biotech/jj-dro…

What were the smartest deals in biopharma over the last few years? The @FierceBiotech team run down some of our favs👀 fiercebiotech.com/biotech/smarte…

@maxonwifi isn't jumping off from Fierce until we've had some fun with him 😎

Great story here from @AGKootenay: "Despite releasing clinical data that included positive phase 3 results, receiving a fast-track designation from the FDA and receiving $10 million in non-dilutive funding, Vaxxinity’s shares still plummeted from the original list price."

We're growing the Fierce Biotech team! The first position we’re adding is a staff writer. We’re seeking someone with a few years of experience, ideally with a background in biotech writing. 🔗 recruiting.ultipro.com/QUE1003QSTX/Jo…

Great interview by @AGKootenay and a reminder of how brutal the public markets can still be for biotechs